Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Konig L,Kappes J,Thomas M,Herth F,Heußel CP,Warth A,Debus J,Steins M,Rieken S M .2017 .Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J. Neurooncol., 134(1) : 205-212.
Besse B,Le Moulec S,Mazieres J,Senellart H,Barlesi F,Chouaid C,Dansin E,Berard H,Falchero L,Gervais R,Robinet G,Ruppert A-M R,Léna H,Clément-Duchêne C,Quantin X,Souquet PJ,Trédaniel J,Moro-Sibilot D,Pérol M,Madroszyk AC,Soria JC .1896 .Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin. Cancer Res., 21(8) : .
Braganca KCD,Janjigian YY,Azzoli CG,Kris MG,Pietanza MC,Nolan CP,Omuro AM,Holodny AI,Lassman AB .2010 .Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol., 100(3) : 443-447.
Cheng JD,Chai LX,Zhao ZP,Hao YY,Li S YY .2020 .Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Manag. Res., 12 : 5641-5650.
Dansin E,Cinieri S,Garrido P,Griesinger F,Isla D,Koehler M,Kohlhaeufl M M .2012 .MO19390 (SAiL): Bleeding events in a phase IV study of firstline bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer, 76(3) : 373-379.
De Graaf JC,Banga JD,Moncada S,Palmer RM,Groot P G,Sixma JJ .1992 .Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 85(6) : 2284-2290.
Fenske DC,Price GL,Hess LM,John WJ,Kim ES .2017 .Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States. Clin. Lung Cancer, 18(6) : 607-614.
Ferrara N .2004 .Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev, 25(4) : 581-611.
Fox BD,Cheung VJ,Patel AJ,Suki D,Rao G .2011 .Epidemiology of metastatic brain tumors. Neurosurg. Clin. N. Am., 22(1) : 1-6.
Ian Z .2001 .Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol Cell Physiol, 280(6) : C1375.
Ling Y,Yang Y,Lu N,You QD,Wang S,Gao Y,Chen Y,Guo QL .2007 .Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Comm., 361(1) : 79-84.
Lukas RV,Kumthekar P,Rizvi S,Salgia R .2016 .Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol., : 1045-1058.
Lu X,Kang Y.,Hypoxia Y.,Hypoxia-Inducible Factors . .. Clin. Cancer Res., 16(24) : 5928-35.
Lynch TJ,Spigel DR,Brahmer J,Fischbach N,Garst J,Jahanzeb M,Kumar P,Vidaver R M A J,Fish S,Flick ED,Leon L,Hazard SJ,Kosty MP . .Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-SmallCell Lung Cancer: Final Results of the ARIES Observational Cohort Study. J. Thorac. Oncol, 9(9) : 1332-1339.
Masuda C,Sugimoto M,Wakita D,Monnai M,Ishimaru C,Nakamura R,Kinoshita M,Yorozu K,Kurasawa M,Kondoh O,Yamamoto K O .2020 .Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clin. Exp, 37(1) : 199-207.
Peng L,Wang Y,Fei S,Wei C H,Tong F,Wu G,Ma H,Dong XR .2020 .The effect of combining Endostar with radiotherapy on blood vessels, tumor-associated macrophages, and T cells in brain metastases of Lewis lung cancer. Transl. Lung Cancer Res., 9(3) : 745-760.
Qin TT,Liu ZJ,Wang J,Xia J L,Liu S C,Jia Y N,Liu H L and Li K Y N .2020 .Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol. Med, 17 : 753-767.
Reck M,Von Pawel J,Zatloukal P,Ramlau R,Gorbounova V,Hirsh V,Leighl N,Mezger J,Archer V,Moore N,Manegold C .2010 .Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). , 21(9) : 1804-1809.
Reck ,Clin .2009 .Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. , 27(8) : 1227.
Rini BI,Sosman JA,Motzer RJ .2005 .Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. BJU Int, 96(3) : 286-90.
Sandler A,Hirsh V,Reck M,Pawel JV,Akerley W,Johnson DH .2012 .An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer, 78(1) : 1-7.
Xu HF,Zhao GP,Yang JJ,Wen XP .2019 .Advances in toxicity risk analysis and effective treatments for targeted antiangiogenic drugs. Int. J. Clin. Exp. Med, 12 : 12020-12027.
Yao SK,Ober JC,Krishnaswami A,Ferguson J J,Anderson HV,Golino P,Buja LM,Willerson JT .1992 .Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation, 86(4) : 1302-1309.
Yongli Z,Jigang D,Bo L,Maojiang L,Yan C,Xiaoxiao L C .2017 .The value analysis of blood brain barrier permeability in the treatment of multiple brain metastases patients with non-small cell lung cancer. J. Mod. Oncol., 14 : 2238-2242.